Búsqueda | Portal de Búsqueda de la BVS España

1.

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Kiesewetter, B; Dafni, U; de Vries, E G E; Barriuso, J; Curigliano, G; González-Calle, V; Galotti, M; Gyawali, B; Huntly, B J P; Jäger, U; Latino, N J; Malcovati, L; Oosting, S F; Ossenkoppele, G; Piccart, M; Raderer, M; Scarfò, L; Trapani, D; Zielinski, C C; Wester, R; Zygoura, P; Macintyre, E; Cherny, N I.

Ann Oncol; 34(9): 734-771, 2023 09.

Artículo en Inglés | MEDLINE | ID: mdl-37343663

2.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock, C; Versluis, J; Labopin, M; Socie, G; Huynh, A; Deconinck, E; Volin, L; Milpied, N; Bourhis, J H; Rambaldi, A; Chevallier, P; Blaise, D; Manz, M; Vellenga, E; Vekemans, M-C; Maertens, J; Passweg, J; Vyas, P; Schmid, C; Löwenberg, B; Ossenkoppele, G; Mohty, M; Cornelissen, J J; Nagler, A.

J Intern Med; 283(4): 371-379, 2018 04.

Artículo en Inglés | MEDLINE | ID: mdl-29214689

3.

The war on clones: a Darwinian enigma.

Cloos, J; Ossenkoppele, G J.

Blood; 137(22): 3008-3009, 2021 06 03.

Artículo en Inglés | MEDLINE | ID: mdl-34081123

4.

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study.

van der Poel, M W M; Mulder, W J; Ossenkoppele, G J; Maartense, E; Hoogendoorn, M; Wijermans, P; Schouten, H C.

Ann Hematol; 94(8): 1373-9, 2015 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-25869027

5.

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

van de Loosdrecht, A A; Cremers, E M P; Alhan, C; Duetz, C; In 't Hout, F E M; Visser-Wisselaar, H A; Chitu, D A; Verbrugge, A; Cunha, S M; Ossenkoppele, G J; Janssen, J J W M; Klein, S K; Vellenga, E; Huls, G A; Muus, P; Langemeijer, S M C; de Greef, G E; Te Boekhorst, P A W; Raaijmakers, M H G; van Marwijk Kooy, M; Legdeur, M C; Wegman, J J; Deenik, W; de Weerdt, O; van Maanen-Lamme, T M; Jobse, P; van Kampen, R J W; Beeker, A; Wijermans, P W; Biemond, B J; Tanis, B C; van Esser, J W J; Schaar, C G; Noordzij-Nooteboom, H S; Jacobs, E M G; de Graaf, A O; Jongen-Lavrencic, M; Stevens-Kroef, M J P L; Westers, T M; Jansen, J H.

Leukemia; 38(4): 840-850, 2024 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-38297135

6.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Russell, Nigel; Douglas, Kenny; Ho, Anthony D; Mohty, Mohamad; Carlson, Kristina; Ossenkoppele, G J; Milone, Giuseppe; Pareja, Macarena Ortiz; Shaheen, Daniel; Willemsen, Arnold; Whitaker, Nicky; Chabannon, Christian.

Haematologica; 98(2): 172-8, 2013 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-22983579

7.

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Janssen, J J W M; Löwenberg, B; Manz, M; Biemond, B J; Westerweel, P E; Klein, S K; Fehr, M; Sinnige, H A M; Efthymiou, A; Legdeur, M C J C; Pabst, T; Gregor, M; van der Poel, M W M; Deeren, D; Tick, L W; Jongen-Lavrencic, M; van Obbergh, F; Boersma, R S; de Weerdt, O; Chalandon, Y; Heim, D; Spertini, O; van Sluis, G; Graux, C; Stüssi, G; van Norden, Y; Ossenkoppele, G J.

Leukemia; 36(9): 2189-2195, 2022 09.

Artículo en Inglés | MEDLINE | ID: mdl-35869267

8.

Evaluating ivosidenib for the treatment of acute myeloid leukemia.

Donker, M L; Ossenkoppele, G J.

Expert Opin Pharmacother; 21(18): 2205-2213, 2020 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-32808831

9.

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; van Marwijk Kooy, M; Maertens, J; Michaux, L; van der Poel, M W M; van Rhenen, A; Tick, L; Valk, P; Vekemans, M C; van der Velden, W J F M; de Weerdt, O; Pabst, T; Manz, M; Löwenberg, B.

Leukemia; 34(10): 2820, 2020 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-32733013

10.

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; van Marwijk Kooy, M; Maertens, J; Michaux, L; van der Poel, M W M; van Rhenen, A; Tick, L; Valk, P; Vekemans, M C; van der Velden, W J F M; de Weerdt, O; Pabst, T; Manz, M; Löwenberg, B.

Leukemia; 34(7): 1751-1759, 2020 07.

Artículo en Inglés | MEDLINE | ID: mdl-32020044

11.

Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.

van de Loosdrecht, A A; van den Ancker, W; Houtenbos, I; Ossenkoppele, G J; Westers, T M.

Handb Exp Pharmacol; (188): 319-48, 2009.

Artículo en Inglés | MEDLINE | ID: mdl-19031033

12.

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.

Reedijk, A M J; Klein, K; Coebergh, J W W; Kremer, L C; Dinmohamed, A G; de Haas, V; Versluijs, A B; Ossenkoppele, G J; Beverloo, H B; Pieters, R; Zwaan, C M; Kaspers, G J L; Karim-Kos, H E.

Leukemia; 33(6): 1349-1359, 2019 06.

Artículo en Inglés | MEDLINE | ID: mdl-30568171

13.

Genotyping by morphology...

Wondergem, M J; Ossenkoppele, G J.

Blood; 117(9): 2566, 2011 Mar 03.

Artículo en Inglés | MEDLINE | ID: mdl-21488251

14.

Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.

van Galen, J C; Muris, J J F; Giroth, C P E; Vos, W; Ossenkoppele, G J; Meijer, C J L M; Oudejans, J J.

Histopathology; 52(5): 578-84, 2008 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-18312353

15.

Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.

Hess, C J; Ameziane, N; Schuurhuis, G J; Errami, A; Denkers, F; Kaspers, G J L; Cloos, J; Joenje, H; Reinhardt, D; Ossenkoppele, G J; Zwaan, C M; Waisfisz, Q.

Cell Oncol; 30(4): 299-306, 2008.

Artículo en Inglés | MEDLINE | ID: mdl-18607065

16.

Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.

van Rhenen, A; Moshaver, B; Kelder, A; Feller, N; Nieuwint, A W M; Zweegman, S; Ossenkoppele, G J; Schuurhuis, G J.

Leukemia; 21(8): 1700-7, 2007 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-17525725

17.

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.

Deenik, W; van der Holt, B; Verhoef, G E G; Schattenberg, A V M B; Verdonck, L F; Daenen, S M G J; Zachée, P; Westveer, P H M; Smit, W M; Wittebol, S; Schouten, H C; Löwenberg, B; Ossenkoppele, G J; Cornelissen, J J.

Ann Hematol; 86(2): 117-25, 2007 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-17031690

18.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan, C S; Gale, R P; Gormley, N J; Ossenkoppele, G J; Walter, R B.

Leukemia; 31(7): 1482-1490, 2017 07.

Artículo en Inglés | MEDLINE | ID: mdl-28386105

19.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann, V S; Baccarani, M; Hasford, J; Castagnetti, F; Di Raimondo, F; Casado, L F; Turkina, A; Zackova, D; Ossenkoppele, G; Zaritskey, A; Höglund, M; Simonsson, B; Indrak, K; Sninska, Z; Sacha, T; Clark, R; Bogdanovic, A; Hellmann, A; Griskevicius, L; Schubert-Fritschle, G; Sertic, D; Guilhot, J; Lejniece, S; Zupan, I; Burgstaller, S; Koskenvesa, P; Everaus, H; Costeas, P; Lindoerfer, D; Rosti, G; Saussele, S; Hochhaus, A; Hehlmann, R.

Leukemia; 31(3): 593-601, 2017 03.

Artículo en Inglés | MEDLINE | ID: mdl-27568522

20.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Versluis, J; In 't Hout, F E M; Devillier, R; van Putten, W L J; Manz, M G; Vekemans, M-C; Legdeur, M-C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J M; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, T; Willemze, R; Löwenberg, B; Ossenkoppele, G; Baron, F; Huls, G; Cornelissen, J J.

Leukemia; 31(1): 26-33, 2017 01.

Artículo en Inglés | MEDLINE | ID: mdl-27416910

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: